The CEO's open-market purchase is a positive signal, but it's offset by a director selling a slightly larger dollar amount. The overall activity is modest and not materially dilutive or accretive. Traders should monitor for follow-up transactions, especially additional buying from the CEO.
IMNM drugs
IMNM drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Mar 23 $20.75entry
- T+1 · 8mo ago −2.60%α −2.25% · $20.21
- T+5 · 8mo ago −6.99%α −3.42% · $19.30
- T+20 · 7mo ago +14.94%α +7.52% · $23.85
- T+60 · 5mo ago −10.70%α −23.76% · $18.53
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Immunome Inc. saw mixed insider activity with CEO Clay Siegall purchasing $501K of stock while Director Philip Wagenheim sold $582K. The trades are modest in size relative to the company's $2.5B market cap, with the CEO's buying signaling confidence despite a director's exit.
Key Financial Metrics
Key Facts
- CEO Clay Siegall purchased 25,450 shares in the open market for $500,601.50 at $19.67 per share on March 27, 2026.
- Director Philip Wagenheim sold 28,200 shares for $582,330 at $20.65 per share on March 23, 2026.
- CSO Jack Higgins gifted 6,291 shares (non-cash transaction) on March 30, 2026.
- Total cluster value: $1.08M, representing 0.04% of the company's $2.5B market cap.
Financial Impact
$1.08M in net insider transactions over 7 days, with $501K in buying and $582K in selling. Non-cash gift of 6,291 shares adds no economic value.
Risk Factors
- Director selling could indicate lack of confidence or portfolio rebalancing.
- Low volume of insider trades limits the strength of the signal.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-IMNM-1775079580899 |
Track record
20 reports on IMNM
3 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +26.53% at T+60 after the May 28, 2026 report. 6 of 8 went positive at some point.
Filters
- Nov 16, 2026today SC 13G Neutral 3/10 Entry $18.39 Now $17.61 −4.24% settles Feb 12
- Nov 9, 20267d ago S-3ASR Neutral 3/10 Entry $18.65 Now $17.61 −5.58% settles Feb 8
- Nov 9, 20267d ago S-3ASR Neutral 3/10 Entry $18.65 Now $17.61 −5.58% settles Feb 8
- Nov 9, 20267d ago 8-K Bearish 5/10 Entry $18.65 Now $17.61 +5.58% settles Feb 8
- Oct 30, 202617d ago SC 13G Neutral 3/10 Entry $18.21 Now $17.61 −3.29% settles Jan 28
- Oct 16, 20264w ago ANALYST-UPGRADE Bullish 4/10 Entry $16.47 Now $17.61 +6.92% settles Jan 13
- Oct 5, 20266w ago 8-K Bullish 6/10 Entry $21.17 Now $17.61 −16.82% settles Dec 30
- Oct 1, 20266w ago ANALYST-UPGRADE Bearish 4/10 Entry $20.89 Now $17.61 +15.70% settles Dec 28
- Sep 21, 20268w ago ANALYST-UPGRADE Bullish 4/10 Entry $25.07 Now $17.61 −29.76% settles Dec 15
- Aug 12, 202613w ago Insider Cluster Neutral 4/10 Entry $26.42 to $18.71 Now $17.61 −33.35% ▼ −29.18% −23.71% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers